China's Pharmaceutical Patent Linkage System Shows Growing Judicial Maturity After Four Years of Operation
核心洞察
China's pharmaceutical patent linkage system has processed 183 administrative adjudication decisions and 50 civil cases since its launch in 2021, with approximately half of cases being voluntarily withdrawn by petitioners.
Courts have established restrictive principles for patent registration eligibility, particularly excluding crystalline form patents (搜索) and limiting medical use patents to active compounds rather than crystalline form-specific uses.
The Supreme People's Court (搜索) has clarified that the 45-day filing deadline operates primarily as a condition for triggering regulatory stays rather than a mandatory jurisdictional requirement for case acceptance.
China's pharmaceutical patent linkage system has reached a significant milestone after four years of operation, with emerging judicial trends revealing how courts and administrative bodies are interpreting the regulatory framework designed to balance patent protection with generic drug market access.
Since the system's launch in July 2021, following the fourth amendment to China's Patent Law, the China National Intellectual Property Administration (搜索) (CNIPA) has published 183 administrative adjudication decisions involving pharmaceutical patents. Of these cases, more than half (98 cases) were voluntarily withdrawn by petitioners, while 37 cases were found to fall within patent protection scope and 34 cases were determined not to infringe patents.
The civil litigation landscape shows similar patterns, with China Judgments Online recording 50 civil judgments and rulings related to the patent linkage system. Approximately 54% of these cases saw plaintiffs voluntarily withdraw their actions during proceedings, with only 9 cases proceeding to substantive trial and resulting in court judgments.
Restrictive Approach to Patent Registration Eligibility
The Supreme People's Court (搜索) (SPC) has taken a notably restrictive stance on which patents qualify for registration under the linkage system. Courts have established that crystalline form patents (搜索) cannot be registered, determining patent classification based on the subject matter and technical features of claims rather than expansive interpretations.
"Whether a patent constitutes a crystalline form patent should be determined based on the subject matter and technical features of the claims," the SPC ruled in multiple decisions. "If the claims do not refer to crystalline characteristics, or lack terminology or characterization specific to crystalline forms, courts should not expansively interpret such claims as covering crystalline forms."
The courts have also clarified that medical use patents under the linkage framework cover uses of active compound patents or composition patents, but exclude pharmaceutical-use claims limited to crystalline forms. This interpretation aligns with legislative intent to prevent overly broad protection while promoting timely generic market entry.
Flexible Interpretation of Filing Deadlines
A key development concerns the 45-day filing deadline specified in the implementation measures. While the regulations state that patentees may file lawsuits within 45 days of a generic drug application's public disclosure, courts have not treated this as a mandatory jurisdictional requirement.
The prevailing judicial view holds that the 45-day period primarily serves as a condition for triggering the nine-month regulatory stay rather than an absolute filing deadline. This interpretation prevents patent holders from being unjustly deprived of linkage system protections due to timing technicalities.
"Treating the 45-day window as jurisdictional could unjustly deprive patent holders of the opportunity to protect their rights under the linkage system, which is contrary to the system's intended purpose," legal practitioners note based on case-handling experience.
Resolution of Timing Conflicts
Courts have developed sophisticated approaches to handle timing conflicts between patent registration and generic drug applications. The SPC has clarified that when marketing authorization holders (MAHs) complete patent registration within the prescribed 30-day period, they should receive reasonable opportunities to request generic applicants amend their declaration categories.
In cases where patent registration occurs after generic applications but within regulatory deadlines, the SPC ruled that "the mere order of registration should not prevent the filing of a lawsuit or administrative adjudication request, especially when the MAH has completed registration within the prescribed 30-day period."
However, practical challenges remain, as current regulations provide no available channels for generic drug applicants to change their declaration categories once submitted.
Burden of Proof Standards
Administrative and judicial bodies have established that generic drug applicants bear the initial evidentiary burden to demonstrate their technical solutions fall outside patent scope. This requirement stems from the principle that applicants, possessing unique access to their registration dossiers, are best positioned to provide technical solutions establishing non-infringement.
The CNIPA has emphasized that disclosure obligations apply regardless of whether generic applicants are requesting or responding parties, and regardless of their declaration categories. However, the required showing is limited to demonstrating "high likelihood" rather than absolute certainty of falling within or outside patent scope.
Accuracy of Patent Registration
The system places responsibility on MAHs for the truthfulness, accuracy, and completeness of registered patent information, while the registration platform conducts only formal examination. The SPC has established that registered patents must actually cover the technical solutions of approved drugs, not merely relate to them in general terms.
"Only where the technical solution of the original drug itself falls within the protection scope of the relevant patent claims can an action brought by the patentee or an interested party be recognized as having the legal basis provided under Article 76, Paragraph 1 of the Patent Law," the SPC ruled in landmark decisions.
System Evolution and Future Outlook
The patent linkage system represents a significant shift in China's pharmaceutical regulatory landscape, linking patent status directly to marketing authorization processes. The mechanism aims to resolve potential patent disputes before generic drugs (搜索) receive approval, balancing innovation incentives with generic access.
As the system continues maturing, practitioners expect further clarification on remaining practical issues, including handling of patents granted after drug approval and standardization of evidence requirements across different case types. The emergence of consistent judicial principles suggests the system is achieving its intended balance between protecting original drug patents and facilitating timely generic market entry.